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Relapse and graft-versus-host disease remain major problems associated with allogeneic bone marrow (BM)
transplantation (allo-BMT) and posttransplantation therapy in patients with multiple myeloma (MM) and
other hematologic malignancies. A possible strategy for selectively enhancing the graft-versus-myeloma
response and possibly reducing graft-versus-host disease is to increase the migration of alloreactive T cells
toward the MM-containing BM. In the present study, we characterized the BM-homing behavior of donor-
derived effector T cells in a novel allo-BMT model for the treatment of MM. We observed that post-
transplantation immunotherapy consisting of donor lymphocyte infusion (DLI) and vaccination with minor
histocompatibility antigen-loaded dendritic cells (DCs) was associated with prolonged survival compared
with allo-BMT with no further treatment. Moreover, CD8þ effector T cells expressing inﬂammatory homing
receptors, including high levels of CD44, LFA-1, and inﬂammatory chemokine receptors, were recruited to
MM-bearing BM. This was paralleled by strongly increased expression of IFN-g and IFN-geinducible che-
mokines, including CXCL9, CXCL10, and CXCL16, especially in mice treated with DLI plus minor histocom-
patibility antigen-loaded DC vaccination. Remarkably, expression of the homeostatic chemokine CXCL12 was
reduced. Furthermore, IFN-g and TNF-a induced BM endothelial cells to express high levels of the inﬂam-
matory chemokines and reduced or unaltered levels of CXCL12. Finally, presentation of CXCL9 by multiple BM
endothelial cell-expressed heparan sulfate proteoglycans triggered transendothelial migration of effector T
cells. Taken together, our data demonstrate that both post-transplantation DLI plus miHA-loaded DC vacci-
nation and MM growth result in an increased expression of inﬂammatory homing receptors on donor T cells,
decreased levels of the homeostatic BM-homing chemokine CXCL12, and strong induction of inﬂammatory
chemokines in the BM. Thus, along with increasing the population of alloreactive T cells, post-transplantation
immunotherapy also might contribute to a more effective graft-versus-tumor response by switching
homeostatic T cell migration to inﬂammation-driven migration.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION response without severe GVHD. For instance, adoptive
Multiple myeloma (MM) is a severe B cell malignancy
characterized by the accumulation of malignant plasma cells
in the bone marrow (BM). Allogeneic BM transplantation
(allo-BMT) or allogeneic stem cell transplantation (allo-SCT)
followed by donor lymphocyte infusion (DLI) can result in
long-term remission [1]. This therapeutic effectiveness is
attributed to the graft-versus-myeloma (GVM) response,
during which donor CD8þ T cells become activated by
recipient minor histocompatibility antigens (miHAs) pre-
sented on dendritic cells (DCs). Consequently, these allor-
eactive T cells migrate to the BM and eradicate miHAþ
myeloma cells. Unfortunately, subsets of alloreactive T cells
migrate to miHAþ healthy tissues, such as the gut, skin, and
liver, resulting in graft-versus-host disease (GVHD), causing
highmorbidity and evenmortality. Thus, a major challenge is
to design a speciﬁc therapy that induces a potent GVMedgment on page 385.
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12.12.014transfer of T cells recognizing miHA speciﬁcally expressed by
malignant cells, including MM cells, or vaccination with DCs
presenting thesemiHA, has recently garnered attention [2,3].
Alternatively, or additionally, strategies that increase the
recruitment of alloreactive T cells to the BM could result in
a more effective GVM response.
Recruitment of activated T cells from the blood into
tissues requires a tightly regulated sequence of adhesion
events between the T cells and endothelial cells of the vessel
wall [4]. Several families of homing receptors are involved in
each of these adhesion events. For instance, selectins are
predominantly involved in rolling on the endothelium, and
chemokine receptors and integrins are involved mainly in
enhanced adhesion and transmigration. Although many of
the homing receptors involved in, for instance, skin homing
and gut homing have been characterized, those participating
in homing to BM, especially inﬂamed BM, remain incom-
pletely deﬁned. Early work with transgenic mice and block-
ing antibodies indicated that the T cell-expressed chemokine
receptor CXCR4 and the adhesionmolecule VCAM-1, which is
constitutively expressed on BM endothelial cells (BMECs),
play major roles in the homing of T cells to healthy BM [5-7].
These results were conﬁrmed by Mazo et al. [8], who
demonstrated that in CD8þ central memory T cells, a major
Transplantation.
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by BM-expressed CXCL12 results in activation of the integrin
a4b1 and subsequent ﬁrm adhesion via VCAM-1. Those
authors also reported that central memory T cells use
carbohydrate ligands of E-selectin and P-selectin to roll on
BMECs, and L-selectin to mediate tethering to already-
adhering leukocytes. Finally, most CD4þ memory T cells in
the BM were shown to express a2 integrins, and a2-blocking
antibodies inhibited their homing to the BM of healthy or
immunized mice [9].
In the present study, we characterized the trafﬁcking
of activated donor T cells to the MM-containing BM of
mice that had undergone allo-BMT with and without
post-transplantation immunotherapy. Our data suggest
that the inﬂammatory environment created by MM
growth and immunotherapy speciﬁcally recruits activated
CXCR6þCXCR3þ donor T cells by inducing the expression of
inﬂammatory chemokines that are subsequently presented
on BMEC heparan sulfate proteoglycans (HSPG).
MATERIALS AND METHODS
Mice
C3.SW-H2b/SnJ (H-2b, Ly9.1þ) mice and OT-1 mice were originally
purchased from The Jackson Laboratory (Bar Harbor, ME). C57Bl/KaL-
wRij.hsd mice were purchased from Harlan Laboratories (Indianapolis, IN).
All mice were maintained on standard lab chow and sterile water and
housed under speciﬁc pathogen-free conditions at the Central Animal
Laboratory. All animal experiments were approved by the Animal Experi-
mental Committee of the Radboud University Nijmegen Medical Centre and
were performed in accordancewith institutional and national guidelines. All
efforts were made to minimize animal suffering.
Allo-BMT, DC Vaccination, DLI, and MM Challenge
C57Bl/KaLwRij.hsd mice aged 8-12 weeks were irradiated with a linear
particle accelerator in 2 treatments of 6 Gy at days -2 and -1 before allo-BMT.
Irradiated mice received 5  106 T cell-depleted C3.SW-H2b/SnJ BM cells i.v.
T cells were depleted using anti-CD4 and anti-CD8 IMagmagnetic beads (BD
Biosciences, San Jose, CA). Between day -7 and day þ7 after allo-BMT, mice
received ciproﬂoxacine in their drinking water. After a 2-month reconsti-
tution period, mice were vaccinated with 5  105 CD11cþMHCIIþ DCs i.v.
Using anti-CD11c magnetic beads (Miltenyi Biotec, Bergisch Gladbach,
Germany), DCs were isolated directly from the BM of C57Bl/KaLwRij.hsd
mice that had been injected s.c. with B16-Flt3L cells 14 days earlier, as re-
ported previously [10]. The percentage of CD11cþMHCIIþ DCs was deter-
mined by ﬂow cytometry, and DCs were loaded with miHA H7a peptide
(KAPDNRETL; Leiden University Medical Centre, Leiden, The Netherlands).
On the next day, the mice were injected with 106 5T33-GFP MM cells [11],
along with DLI in the form of 2107mononuclear cells from C3.SW-H2b/SnJ
spleens and peripheral lymph nodes. In some experiments, nontransplanted
C57Bl/KaLwRij.hsd mice with and without 106 5T33-GFP MM cells were
analyzed.
Genotype Analysis
Genomic DNAwas isolated from cell lines using the QIAamp DNA Blood
Mini Kit (Qiagen, XXX). 100 ng DNA was ampliﬁed in a 50-mL reaction
mixture containing 1.25 U AmpliTaq Gold (Life Technologies, Carlsbad, CA),
300 nmol/L MiHA-speciﬁc forward and reverse primers (Biolegio, Nijmegen,
The Netherlands), 250 mmol/L of each dNTP (Life Technologies), 5 mmol/L
MgCl2, and 1 Taqman PCR buffer (Life Technologies, Carlsbad, CA). PCR
ampliﬁcationwas performed using a PerkinElmer Cetus DNA Thermal Cycler
(Waltham, MA) under the following PCR conditions: enzyme activation for
10minutes at 95C, followed by 35 cycles of 15 seconds at 95C and 1minute
at 66C. PCR products were analyzed on a 2% agarose Tris-borate-EDTA gel.
RNA Isolation and Quantitative RT-PCR
RNA was isolated and ampliﬁed by quantitative RT-PCR (qPCR) as
described previously [10]. Primers and probes are listed in Table S1.
Expression was normalized against the reference gene porphobilinogen
deaminase (PBGD) using the 2-DCt method, where DCt represents the
threshold cycle (Ct) of the sample gene minus the Ct of PBGD.
Flow Cytometry, Cell Sorting, and Antibodies
BMwas isolated by ﬂushing femurs and tibia with buffer. Staining of cell
surface proteins was performed as described previously [10]. Ex vivo 5T33-GFP MM cells were sorted on an EPICS ELITE Cell Sorter (Beckman Coulter,
Brea, CA). Then MM cells (93%-98% pure) were lysed for RNA isolation.
Except when noted otherwise, antibodies were purchased from BD
Biosciences. Along with the isotype controls FITC-conjugated mouse IgG2b
and rat IgG2a (eBioscience); hamster IgG, PE-conjugated rat IgG1, IgG2a, and
IgG2b (all eBioscience); and hamster IgG, PE-Cy5-conjugated rat IgG2a
(eBioscience), the following rat antibodies were used: syndecans-4; bio-
tinylated CD3, CD11b (eBioscience); B220/CD45R, FITC-conjugated CD4,
CD62L (ImmunoTools, Friesoyrth, Germany); H2-Db, Ly9.1/CD229.1, PE-
conjugated CD4, a4/CD49d, a4b7, aL/CD11a (eBioscience); CD86, CCR5,
CXCR3 (R&D Systems, Minneapolis, MN); CXCR4 (BD Biosciences and R&D
Systems), CXCR6 (R&D Systems); PSGL-1/CD162, I-A/I-E; PE-Cy5-conjugated
CD44; APC-conjugated syndecan-1; and PE-Cy7-conjugated CD8. In addi-
tion, we used mouse anti-heparan sulfate (10E4) [12]; mouse anti-VSV
(Sigma-Aldrich, St Louis, MO); goat anti-glypican-1 (Santa Cruz Biotech-
nology, Santa Cruz, CA); biotinylated goat anti-mouse CXCL9 and CXCL10
(both R&D Systems); FITC-conjugated mouse anti-H-2Db and hamster anti-
CD11c; Alexa Fluor 488-conjugated goat anti-mouse IgG (Life Technologies),
Alexa Fluor 488-conjugated goat anti-mouse IgM (Life Technologies); Alexa
Fluor 647-conjugated hamster anti-CD11c (AbD Serotec, Kidlington, UK);
PE-conjugated hamster anti-CD80; and control (MPB49) and anti-
chondroitin sulfate single chains (IO3H10) [13].
ELISA on Soluble Material from Tissues
Soluble material from tissues was isolated essentially as described
previously [14]. In brief, BM (from 2 femurs and 2 tibias) single-cell
suspensions were prepared in PBS with proteinase cocktail inhibitor
(P8340; Sigma-Aldrich). Next, insoluble material was separated from
soluble material by 3 consecutive rounds of centrifugation. A sandwich
ELISA for mouse CXCL9 was performed in accordance with the manufac-
turer’s instructions (R&D Systems). We performed ELISAs for mouse IFN-g
and CXCL16 as described previously [10]. The detection limit of these ELISAs
was w16 pg/mL for IFN-g, w60 pg/mL for CXCL9, and w24 pg/mL for
CXCL16.
BMEC Stimulation and Chemokine Binding
The BMEC lines STR-4, STR-10, and STR-12 [15] were cultured in RPMI
1640 medium supplemented with 1 mM sodium pyruvate, nonessential
amino acids (all Life Technologies), 1% penicillin and streptomycin, and 10%
FCS (Integro, Zaandam, The Netherlands). For analysis of chemokine
expression, BMECs were stimulated with IFN-g and/or TNF-a (Immuno-
Tools) for 2 days. For analysis of chemokine binding to heparan sulfate,
BMECs were incubated in Iscove’s modiﬁed Eagle’s medium (IMDM) with
0.5% BSA with or without 500 mU/mL heparinase I, II, and II or 1 U/mL
chondroitinase ABC (all Sigma-Aldrich) for 1 hour at 37C. Next, cells were
extensively washed and incubated with 10 mg/mL CXCL9 or CXCL10
(ImmunoTools) in PBS for 30 minutes at 4C. After washing, cells were
analyzed by ﬂow cytometry for expression of heparan sulfate and immo-
bilized chemokines.
Adhesion and Migration Assays
CD8þ effector T cells were generated by culturing OT-1 splenocytes in
the presence of OVA peptide (SIINFEKL; Leiden University Medical Center) in
T cell medium (IMDM with L-glutamine supplemented with 25 mM Hepes,
10 mM sodium pyruvate, 1 nonessential amino acids, 1% penicillin and
streptomycin, 50 mM b-mercaptoethanol (all Life Technologies), and 10% FCS
(Integro) in a humidiﬁed incubator at 37C for 7-9 days. Migration assays
without shear ﬂow were performed with Transwell Costar (Corning Life
Sciences, Corning, NY) as described previously [10].
Adhesion and migration assays under ﬂow conditions were performed
essentially as described previously [16]. In short, BMECs were cultured to
conﬂuence on gelatin-coated coverslips and assembled in a Focht FCS-2
laminar ﬂow chamber (Bioptechs, Butler, PA). The chamber was then
rinsed and ﬁlled with HBSS (Lonza, Basel, Switzerland) supplemented with
10 mM Hepes (Life Technologies), 0.2% BSA, 1 mM CaCl2$2H2O and
MgCl2$6H2O (all Sigma-Aldrich) at pH 7.4 (TEMmedium), with or without 1
mg/mL CXCL9 (ImmunoTools) for 5 minutes, and then washed extensively
before T cell perfusion. Subsequently, CD8þ effector T cells (1-4  106/mL)
were perfused in TEMmedium into the chamber and, at a shear stress of 0.18
dyne/cm2 for 5 minutes, allowed to accumulate and settle on the BMEC
monolayer. Shear stress was then adjusted to 2 dynes/cm2, a physiological
level known to support transendothelial migration [17], for 15 minutes. All
experiments were performed at 37C. Video recordings of 1-4 microscopic
ﬁelds (0.418 mm2) were read (1 image every 10 seconds) and then analyzed
with an in-house software program. The sizes of 4 types of T cells were
determined: (1) detaching or (2) stationary/arrested during the migration
phase and locomotive from the site of an initial stationary attachment (3)
without or (4) with subsequent transendothelial migration, as described
Figure 1. DLI and miHA-loaded DC vaccination induce superior GVM responses. (A) Scheme showing the treatment schedule of this allo-SCT mouse model. C57BL/
KaLwRij mice were irradiated twice and underwent allo-HCT with T cell-depleted BM of MHC-matched, miHA-mismatched C3.SW-H2b/SnJ (C3.SW) mice. After
a repopulation period of 2 months, mice were vaccinated with unloaded DCs or with DCs loaded with miHA H7 peptide, and received a MM challenge and DLI the
next day. The mice were then evaluated for the development of GVM and GVHD. (B) Kaplan-Meier curves showing the survival of mice treated with allo-SCT only
(BMT), BMT plus MM, and BMT MM mice treated with DLI only or in combination with unloaded or H7-loaded DC vaccination. Data are the combined result of 2
similar experiments. Each group comprised 10-16 mice. Median survival times and P values <.05 are shown.
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experiment were not scored.
Statistical Analysis
Survival rates and differences between groups were calculated by the
Kaplan-Meier product-limit method and the Mantel-Cox log-rank test,
respectively, using SPSS software (IBM, Armonk, NY). The 2-sample t test
and 1-way analysis of variance were applied to identify signiﬁcant differ-
ences between 2 groups or among more than 2 groups, respectively, using
Prism 4 software (GraphPad Software, San Diego, CA). P values <.05 were
considered signiﬁcant.
RESULTS
CD8þ Effector T Cells Inﬁltrate the BM of MM-Bearing
Allo-BMT Recipient Mice
To study the trafﬁcking of donor T cells after allo-BMTand
post-transplantation therapy, we ﬁrst transplanted irradi-
ated C57Bl/KaLwRij.hsd mice with T cell-depleted BM of
MHC-matched, miHA-mismatched C3.SW-H2b/SnJ mice
(Figure 1A). Two months later, after these mice had achieved
full donor chimerism (data not shown), 1 group of mice was
left untreated and the other group was challenged with the
C57Bl/KaLwRij.hsd-derived MM cell line 5T33. These MM
cells display characteristics of human myeloma, including
dominant BM-homing capacity, expression of idiotype
protein and IL-6, and osteolytic-inducing activity [11,18]. In
addition, 1 group of mice with MM was treated with DLI,
another group was treated with DLI plus unloaded DCs, and
a ﬁfth group was treated with DLI plus DCs loaded with the
immunodominant miHA H7. We chose this miHA because
5T33 MM cells express the same genotype as their parental
C57Bl/KaLwRij.hsd mice (which is mismatched with that of
C3.SW-H2b/SnJ mice), express substantial levels of the mRNA
encoding H7, and express H2-Db, which is necessary for the
presentation of H7 (Figure S1). Whereas DLI prolonged the
median survival from 25 days to 34 days (P < .001), addi-
tional H7þ DC vaccination extended the median survival to
47 days (P< .05) without inducing GVHD (Figure 1B and data
not shown). Vaccination with unloaded DCs did not improve
survival of the mice treated with DLI.
We next assessed the cellularity and T cell inﬁltrate of the
BM. We found that the BM of moribund mice with MM was
aplastic, but did not contain different numbers of CD4þ and
CD8þ T cells (Figure 2). We observed similar BM hypoplasia
in nontransplanted C57Bl/KaLwRij.hsd mice, suggesting that
MM growth, not the immunologic milieu created by alloge-
neic transplantation, is the major cause of this phenomenon
(data not shown). Moreover, MM, DLI, and/or H7þ DC
vaccination had no effect on the high percentage (w70%) ofCD4þ effector/effector memory T cells (Figure 2C). In
contrast, the percentage of CD8þ effector/effector memory T
cells was doubled in the BM ofmicewithMM compared with
control mice, irrespective of post-transplantation treatment
(Figure 2D). We found no difference in the percentage of
either CD4þ or CD8þ central memory T cells. These data
demonstrate that increased numbers of CD8þ effector/
effector memory T cells migrate into MM-containing
BM compared with the BM of BMT recipient mice
without MM.
BM-Inﬁltrating CD8þ T Cells Express Effector Homing
Receptors
Because the BM of MM-bearing mice showed increased
inﬁltration of CD8þ effector T cells, we compared the
expression of a panel of putative BM-homing receptors by
BM T cells from the 4 experimental groups described
above. As expected in view of the increased numbers of
CD8þCD62L-CD44hi effector/effector memory T cells
(Figure 2D), we found an increase in CD44 levels and
a decrease in the percentage of CD62L-expressing CD8þ T
cells in MM-containing BM (Figure 3A and Figure S2).
Moreover, these BM T cells demonstrated increased expres-
sion of the integrin lymphocyte function-associated antigen
1 (LFA-1/aLb2). MM-bearing BM also contained more CD8þ T
cells expressing the inﬂammatory chemokine receptor
CXCR6. Remarkably, fewer CD4þ T cells and CD8þ T cells
expressing the inﬂammatory chemokine receptor CXCR3
were detected inMM-bearing BM. Because CXCR3 is a typical
inﬂammatory chemokine receptor expressed almost exclu-
sively by effector and memory T cells, our data suggest that
the recruited T cells had endocytosed CXCR3 on ligand
binding. To investigate this possibility, we quantiﬁed the
expression of CXCR3 mRNA by qPCR, as described previously
[19]. As shown in Figure 3B, MM-bearing BM contained
approximately 10-fold more CXCR3 mRNA, suggesting that
MM growth recruited CXCR3þ effector T cells into the BM,
and that CXCR3 was subsequently internalized on ligand
binding. With respect to expression of the aforementioned
homing receptors, we observed no major differences in the
DLI and DLI plus DC vaccination groups compared with the
MM group. Finally, we found no differences in P-selectin
glycoprotein ligand 1 (PSGL-1) and the integrin chain a4,
which represents a4b1, given that the other binding partner
of a4, b7, was not expressed. These data indicate that MM-
bearing BM is inﬁltrated by donor T cells with an effector
homing phenotype.
Figure 2. Increased inﬁltration of CD8þ effector T cells in the BM of allo-BMT recipient mice bearing MM. Shown are absolute numbers of BM cells (A) and BM T cells
(B), and percentages of activated CD4þ BM T cell subsets (C) and CD8þ BM Tcell subsets (D) of mice treated with allo-BMT (BMT) with or without MM, with or without
DLI, and with or without H7þDC vaccination. T cell percentages were determined by ﬂow cytometry. Effector/effector memory T cells (TEF/EM) and central memory
T cells (TCM) were characterized as CD44hiCD62L- and CD44hiCD62Lþ, respectively. Data are the combined results of at least 3 analyses, with 4-13 mice analyzed per
group. *P < .05; **P < .01; ***P < .001, compared with the BMT group.
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Chemokines and IFN-g in MM-Bearing BM
Based on our ﬁndings showing activation of CD8þ effector
T cells by MM-containing BM recruits, we investigated the
expression of a panel of chemokines involved in effector T
cell attraction. mRNAs of the inﬂammatory chemokines
CXCL9, CXCL10, CXCL11 (all ligands of CXCR3), and CXCL16
(the sole ligand of CXCR6) were more than 10-fold up-
regulated in MM-bearing BM (Figure 4A). Interestingly, this
up-regulationwasmost evident in the group vaccinatedwith
H7-loaded DCs (BMT versus H7þ DCs, P < .01 for CXCL9,
CXCL10, and CXCL16, P < .05 for CXCL11). In contrast, the
homeostatic chemokine CXCL12 (ligand of CXCR4) was
down-regulated by MM growth with or without post-
transplantation therapy. qPCR analysis demonstrated that
sorted MM cells from BM hardly expressed the foregoing
chemokines (Figure 4B), indicating that the up-regulated
chemokines were produced not by the MM cells, but rather
by immune cells or stromal cells.
Next, as proof of principle, we examined whether the
increased expression of chemokine mRNA was also reﬂectedin CXCL9 and CXCL16 protein levels. We found that Indeed,
MM-bearing BM showed an up to 10-fold induction of both
inﬂammatory chemokines as compared to control BM
(Figure 4C). Importantly, DLI plus H7þDC vaccination
induced an additional increase in CXCL16 levels, as compared
to the levels in the BM of MM mice (P < .05). Finally, we
analyzed for between-group differences in levels of the
inﬂammatory cytokine IFN-g, a major inducer of inﬂamma-
tory chemokines [20-22]. Again, elevated IFN-g levels were
detected in the BM of MM mice (Figure 4D), particularly in
the DC vaccination group (P < .01 for BMT versus H7þ DCs).
Taken together, these data demonstrate that the BM of mice
with MM, especially those treated with DLI plus miHA-
loaded DC vaccine, contains signiﬁcantly elevated levels of
inﬂammatory chemokines and their inducer IFN-g.
Activated BMECs Trigger CD8þ Effector T Cell
Transmigration by Presenting Inﬂammatory Chemokines
on Heparan Sulfate Proteoglycans
To determine whether BM-expressed inﬂammatory che-
mokines induce effector T cells to inﬁltrate the BM, we
Figure 3. BM-inﬁltrating CD8þ T cells have a distinct effector homing phenotype. (A) CD4þ T cells and CD8þ T cells isolated from the BM of 4 experimental groups
were assessed for the expression of a panel of homing receptors. Levels of receptors with a gradual expression pattern (CD44, PSGL-1, LFA-1 and a4b1) are presented
as mean ﬂuorescence intensity. The levels of homing receptors expressed on discrete T cell populations (CD62L, CXCR3, and CXCR6) are displayed as percentage of
positive cells. Data are the combined results of at least 3 analyses. Groups comprised 4-9 mice. *P < .05; **P < .01; ***P < .001, compared to the BMT group. (B) CXCR3
mRNA levels in the BM (femurs and tibias) of the experimental groups, as determined by qPCR. Data are the combined result of 2 analyses, with 7-8 mice analyzed per
group. P values <.05 are shown below the panels.
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activated BMECs. We cultured three BMEC lines (STR-4, STR-
10, and STR-12) in plain medium or in medium containing
increasing concentrations of the inﬂammatory cytokines
IFN-g and/or TNF-a, and analyzed their expression of che-
mokine mRNAs by qPCR. Cytokine-activated BMECs
expressed up to 5000-fold higher levels of CXCL9, 300-fold
more CXCL10, 1000-fold more CXCL11, and 40-fold more
CXCL16 than resting BMECs, which expressed only modest
levels of CXCL10 and CXCL12 (Figure 5). In contrast, IFN-g had
no effect on the level of CXCL12 expression, whereas TNF-
a with or without IFN-g reduced expression slightly. Thus,
inﬂammatory conditions induced BMECs to express very
high levels of inﬂammatory chemokines, whereas the
CXCL12 expression was hardly affected or even reduced.
We next examined whether BMECs express HSPGs, on
which they can present chemokines to T cells in the circu-
lation. BMECs indeed expressed high levels of heparan
sulfate, as determined by ﬂow cytometry (Figure 6A).Furthermore, qPCR for a broad panel of major HSPG
demonstrated that BMEC expressed mRNAs for all 4 synde-
cans, 3 of 6 glypicans, and CD44 isoforms containing exon v3,
which encodes the heparan sulfate attachment site
(Figure 6B). Three of the expressed HSPGs with available
antibodies were indeed expressed at the cell surface
(Figure 6C).
To investigate whether BMECs can present chemokines
on HSPGs, we loaded BMECs with CXCL9 or CXCL10, washed
the cells extensively, and then analyzed for the presence of
these chemokines by ﬂow cytometry. Both chemokines were
readily detected on the surface of the BMECs (Figure 6D).
Moreover, the disappearance of both CXCL9 and CXCL10 on
heparan sulfate cleavage by heparinases indicates that the
chemokines were presented on HSPGs (Figure 6E).
Finally, we examined whether inﬂammatory chemokines
presented on BMEC HSPGs are involved in the inﬁltration of
BM by CD8þ effector T cells. We cultured effector T cells from
splenocytes of OT-1 TCR-transgenic mice, whose BM
Figure 4. MM growth and post-transplantation therapy strongly increase the expression of inﬂammatory chemokines and IFN-g in the BM. (A) mRNA levels of the
inﬂammatory chemokines CXCL9, CXCL10, CXCL11, and CXCL16 and the homeostatic chemokine CXCL12 in the BM (femurs and tibias) of the experimental groups.
(B) Chemokine mRNA levels in ex vivo MM cells (n ¼ 2) sorted from the BM of BMT MM mice. (C) mRNA expression levels of CXCL9 and CXCL16 protein in the
experimental groups. (D) mRNA expression levels of proinﬂammatory cytokine IFN-g in the experimental groups. mRNA levels were determined by qPCR; protein
levels, by ELISA. Data are the combined results of at least 3 analyses, with 5-10 mice analyzed per group. P values <.05 are shown below each panel.
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T cells expressed high levels of CXCR3 and migrated in
response to CXCL9 (Figure 7A and B). Importantly, under
physiological shear ﬂow conditions in a laminar ﬂow
chamber, the effector T cells interacted with BMECs and
engaged in transendothelial migration on recognition of
CXCL9 presented by the BMECs (Figure 7C; P < .05). Taken
together, these data demonstrate that proinﬂammatory
cytokines, including IFN-g and TNF-a, induce BMECs to
express high levels of inﬂammatory chemokines, which
trigger effector T cell transmigration on presentation by
BMEC HSPGs.
DISCUSSION
Although allo-BMT followed by DLI can result in long-
term remission in patients with MM, relapse and GVHD
remain major problems. Targeting the migration of activated
donor T cells to the MM-containing BM could contribute to
a more effective GVM response and decreased GVHD. Thus,
we explored the homing mechanisms that donor T cells use
to enter healthy and MM-bearing BM. First, using a novel
mouse model for the treatment of MM with allo-BMT and
post-transplantation therapy, we observed that DLI, partic-
ularly DLI plus miHA H7-loaded DC vaccine, prolonged
survival without inducing GVHD. Importantly, we found no
additive effect on survival after vaccination with unloadedDCs, indicating that the vaccination with H7-loaded DCs had
induced a GVM response targeting H7-presenting MM cells.
We next showed that MM-containing BM contained
a higher percentage of CD8þ effector/memory T cells, but not
CD8þ central memory T cells or activated CD4þ T cells, with
an effector homing phenotype. Thus, most CD8þ T cells
expressed high levels of CD44 and the integrin LFA-1/aLb2,
were negative for the selectin CD62L, and were generally
involved in lymph node homing, and a considerable
percentage expressed the chemokine receptor CXCR6.
Interestingly, the latter ﬁnding was correlated with a strong
increase in the expression of ligand CXCL16 in the BM. In
addition, most CD8þ effector cells expressed integrin a4b1,
which has been shown to be an important mediator of T cell
adhesion and homing to the BM via binding to VCAM-1 [6,8].
Remarkably, the percentages of CD4þ and CD8þ T cells
expressing the inﬂammatory chemokine receptor CXCR3
were reduced compared with the high percentage of CXCR3þ
T cells in the BM of control mice. qPCR analysis indicated that
CXCR3 levels were actually increased by 10-fold, however.
Thus, it is tempting to speculate that the cell surface CXCR3
was decreased owing to endocytosis on binding of its
abundant ligands CXCL9, CXCL10, and CXCL11 in MM-
containing BM. Interestingly, the CXCR6þCXCR3- phenotype
of murine CD8þ T cells in MM-containing BM is identical to
the phenotype of virus-speciﬁc CD8þ T cells homing to the
Figure 5. IFN-g and TNF-a induce the expression of inﬂammatory chemokines by BMECs. mRNA levels of the chemokines CXCL9, CXCL10, CXCL11, CXCL12, and
CXCL16 in BMEC STR-12 were determined by qPCR. BMECs were cultured in the presence of the indicated concentrations of IFN-g, TNF-a, or IFN-g plus 10 ng/mL
TNF-a for 2 days. Data are mean  SD of duplicates. Results are representative of 2 experiments. AU, arbitrary units.
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view of the general inﬂammation-dependent expression of
the CXCR6 and CXCR3 ligands [22], we consider this homing
phenotype to be not BM-speciﬁc, as suggested by those
authors, but rather inﬂammation-speciﬁc.
Lymphocytes enter lymphoid organs and inﬂamed tissues
through a cascade of interactions with the endothelium,Figure 6. BMECs present inﬂammatory chemokines on multiple HSPGs. (A) BMECs s
(bold line) versus isotype control (stippled line). (B) RT-PCR with a panel of HSPG-sp
expression of syndecans-1, syndecans-4, and glypicans-1 (bold lines) versus isotype
loaded with CXCL9 or CXCL10, washed, and analyzed by ﬂow cytometry for the prese
sulfate (CS) with or without enzymatic treatment of BMECs (left). BMEC-bound CXCL9
not after removal of chondroitin sulfate (right). Relative expression is in delta mean
control. One representative experiment out of 3 experiments is shown.including rolling, strong adhesion on recognition of chemo-
kines, and transmigration [4]. Several adhesion and migra-
tion receptors involved in the homing of cultured central
memory T cells to healthy BM have been characterized
previously [8]. Here we extend those ﬁndings by reporting
the mechanisms exploited by allogeneic T cell homing to
inﬂamed BM. For instance, the high expression of PSGL-1 onhow high expression of heparan sulfate on staining with anti-heparan sulfate
eciﬁc primers shows expression of 8 of 11 HSPGs by BMECs. (C) BMEC surface
controls (stippled lines), as determined by ﬂow cytometry. (D) BMECs were
nce of the chemokines. (E) Expression of heparan sulfate (HS) and chondroitin
and CXCL10 are released on the cleavage of heparan sulfate by heparinases, but
ﬂuorescence intensity (MFI) means MFI of the speciﬁc marker minus isotype
Figure 7. BMEC-presented inﬂammatory chemokines induce transendothelial migration of effector T cells. (A) CD8þ effector T cells express high levels of CXCR3.
Peptide-activated splenocytes from OT-1 mice were cultured for 7 days and then stained for CXCR3 (ﬁlled histogram) or isotype control (stippled line). (B) CD8þ
effector T cells migrate in response to CXCL9 under shear-free conditions in Transwells. Data represent mean  SD of duplicates. (C) Presentation of CXCL9 by BMECs
induces transendothelial migration of CD8þ effector T cells. OT-1 effector T cells interacting with control BMECs or CXCL9-loaded BMECs during physiological sheer
ﬂow (2 dynes/cm2) were divided into 4 groups based on migratory phenotype: detachment, stationary arrest, locomotion, and transendothelial migration. Results are
mean  SEM of 4 experiments. *P ¼ .02.
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BM-homing T cells roll on the endothelium by interacting
with P-selectin and E-selectin. However, where especially
the chemokine CXCL12 is involved in the transition from
rolling to sticking in healthy conditions, our data suggest
a dominance of inﬂammatory chemokines in mice with MM.
For instance, we demonstrated that MM growth, especially
when combined with DLI and miHA-loaded DC vaccination,
up-regulated expression of the inﬂammatory chemokines
CXCL9, CXCL10, CXCL11, and CXCL16, whereas the "homeo-
static" chemokine CXCL12 was down-regulated. Reduced
expression of CXCL12 in the BM is correlated with the
mobilization of immunosuppressive BM regulatory T cells to
the circulation [24,25], suggesting reduced suppression of
activated T cells in the BM of mice with MM. In line with our
ﬁndings, Mueller et al. [14] reported transient up-regulation
of the inﬂammatory chemokines CCL2 and CCL5 and down-
regulation of the homeostatic chemokines CCL21 and
CXCL13 in the spleens of mice infected with Listeria mono-
cytogenes. Reduced expression of CCL21 and CXCL13 resulted
in decreased homing and/or retention of naïve lymphocytes
and DCs to the spleen, and was hypothesized to regulate the
cellularity of lymphoid organs. Mueller et al. also identiﬁed
IFN-g as the main inducer of CCL21 and CXCL13 down-
regulation. Thus, IFN-g orchestrates the balance between
inﬂammatory and homeostatic chemokines.
HSPGs are major players in the concentration, posi-
tioning, and presentation of chemokines on endothelial and
other cells, and in preventing the loss of chemokines in the
circulation [26]. Thus, HSPGs are crucial for chemokine-
induced integrin activation and transendothelial migration.
We found that BMECs express a broad panel of HSPGs,
including 7 syndecans and glypicans, on which they present
chemokines with afﬁnity for heparan sulfate, including the
CXCR3 ligands CXCL9 and CXCL10 [27,28]. We also demon-
strated that the interaction of CXCL9 and CXCL10with BMECs
depends on the presence of heparan sulfate, but not chon-
droitin sulfate. Importantly, presentation of CXCL9 by BMECs
induced the transmigration of effector T cells during ﬂow
conditions. These data are in line with a previous report that
presentation of CXCL10 by HSPGs on the endothelium of
coronary arteries induced transmigration of human T cells
[28].
Alteration of the trafﬁcking behavior of alloreactive T cells
to reduce the development of GVHD has been studiedextensively [29,30]. For instance, allo-BMT recipient mice
receiving allogeneic T cells deﬁcient in b7 integrins or CCR2
showed less inﬁltration of the liver and intestine and
decreased GVHD compared with mice receiving WT T cells
[31,32]. Interestingly, b7-/- T cells induced enhanced graft-
versus-tumor reactions. Moreover, CCR5þ effector T cells
inﬁltrate the skin during acute GVHD, CCR5-blocking anti-
bodies reduce inﬁltration and damage to the liver by CD8þ T
cells, and transplant recipients harboring a CCR5 deletion
mutation develop less acute GVHD [33-35]. However, the
worse GVHD in conditioned mice receiving CCR5-/- T cells
suggests that CCR5 might not be the most straightforward
target for strategies aimed at reducing GVHD [36]. Alterna-
tively, direct positioning of donor T cells by intra-BM injec-
tion has been shown to prevent GVHD [37]. Increased
homing of alloreactive T cells to inﬂamed MM-bearing BM
might be achieved through induction or transgenic over-
expression of inﬂammatory homing receptors (eg, CXCR3,
CXCR6) or their ligands. An alternative strategy could be the
vaccination of allo-BMT recipient mice with miHA-loaded
DCs freshly isolated from the BM. Tissue-derived DCs,
particularly those from the skin-draining and gut-draining
lymphoid organs, have been reported to activate tissue-
speciﬁc homing programs in activated T cells [38]. Thus,
the hypothesis that BM-resident DC could target T cells to the
BM is appealing. Our preliminary data using allo-BMT
recipient mice indeed suggest that vaccination with DCs
isolated from the BM induce stronger GVM responses than
vaccination with spleen DCs (data not shown).
In conclusion, in the present study, using a novel mouse
model for allo-BMT, we have demonstrated that MM growth
strongly increases the expression of IFN-geinducible
inﬂammatory chemokines, resulting in the recruitment of
allogeneic CD8þ effector Tcells to the BM. These data indicate
that the mechanisms involved in BM homing are functional
in allo-BMT recipient mice with MM. Thus, we hypothesize
that a more effective GVM response could be accomplished
by increasing the number of alloreactive T cells (eg, bymiHA-
presenting DC vaccination) and/or reducing suppressive
mechanisms, including the programmed death 1 pathway,
acting in the BM.
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